JP2013505268A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013505268A5 JP2013505268A5 JP2012529971A JP2012529971A JP2013505268A5 JP 2013505268 A5 JP2013505268 A5 JP 2013505268A5 JP 2012529971 A JP2012529971 A JP 2012529971A JP 2012529971 A JP2012529971 A JP 2012529971A JP 2013505268 A5 JP2013505268 A5 JP 2013505268A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- sparc
- antibody
- sms
- mammal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 83
- 241000124008 Mammalia Species 0.000 claims 29
- 210000001519 tissue Anatomy 0.000 claims 24
- 210000002950 fibroblast Anatomy 0.000 claims 22
- 238000000034 method Methods 0.000 claims 22
- 238000012744 immunostaining Methods 0.000 claims 19
- 210000004204 blood vessel Anatomy 0.000 claims 16
- 239000003814 drug Substances 0.000 claims 16
- 210000004969 inflammatory cell Anatomy 0.000 claims 16
- 229940124597 therapeutic agent Drugs 0.000 claims 16
- 238000010186 staining Methods 0.000 claims 14
- 210000004881 tumor cell Anatomy 0.000 claims 14
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 10
- 201000002528 pancreatic cancer Diseases 0.000 claims 10
- 239000002246 antineoplastic agent Substances 0.000 claims 9
- 229940127089 cytotoxic agent Drugs 0.000 claims 9
- 239000011159 matrix material Substances 0.000 claims 9
- 230000001537 neural effect Effects 0.000 claims 9
- 229960001592 paclitaxel Drugs 0.000 claims 8
- 238000009104 chemotherapy regimen Methods 0.000 claims 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 6
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 6
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 claims 5
- 206010006187 Breast cancer Diseases 0.000 claims 5
- 208000026310 Breast neoplasm Diseases 0.000 claims 5
- 210000003484 anatomy Anatomy 0.000 claims 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- 208000007860 Anus Neoplasms Diseases 0.000 claims 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 3
- 208000018084 Bone neoplasm Diseases 0.000 claims 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 3
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims 3
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 3
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 3
- 206010061968 Gastric neoplasm Diseases 0.000 claims 3
- 208000032612 Glial tumor Diseases 0.000 claims 3
- 206010018338 Glioma Diseases 0.000 claims 3
- 206010019695 Hepatic neoplasm Diseases 0.000 claims 3
- 208000017604 Hodgkin disease Diseases 0.000 claims 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 3
- 206010027476 Metastases Diseases 0.000 claims 3
- 208000034578 Multiple myelomas Diseases 0.000 claims 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 3
- 206010029098 Neoplasm skin Diseases 0.000 claims 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 229930012538 Paclitaxel Natural products 0.000 claims 3
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims 3
- 208000002471 Penile Neoplasms Diseases 0.000 claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 3
- 206010039491 Sarcoma Diseases 0.000 claims 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 3
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 3
- 210000000988 bone and bone Anatomy 0.000 claims 3
- 210000000845 cartilage Anatomy 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 210000003169 central nervous system Anatomy 0.000 claims 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 208000023963 corpus uteri neoplasm Diseases 0.000 claims 3
- 201000011523 endocrine gland cancer Diseases 0.000 claims 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims 3
- 201000004959 laryngeal benign neoplasm Diseases 0.000 claims 3
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 208000014018 liver neoplasm Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 208000037841 lung tumor Diseases 0.000 claims 3
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 230000009401 metastasis Effects 0.000 claims 3
- 208000025402 neoplasm of esophagus Diseases 0.000 claims 3
- 208000025189 neoplasm of testis Diseases 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- 208000025303 orbit neoplasm Diseases 0.000 claims 3
- 201000000890 orbital cancer Diseases 0.000 claims 3
- 208000011252 penile benign neoplasm Diseases 0.000 claims 3
- 208000023974 pharynx neoplasm Diseases 0.000 claims 3
- 201000001514 prostate carcinoma Diseases 0.000 claims 3
- 208000023958 prostate neoplasm Diseases 0.000 claims 3
- 208000013718 rectal benign neoplasm Diseases 0.000 claims 3
- 201000008946 renal pelvis neoplasm Diseases 0.000 claims 3
- 208000028466 reproductive system neoplasm Diseases 0.000 claims 3
- 210000002345 respiratory system Anatomy 0.000 claims 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 3
- 208000014680 small intestine neoplasm Diseases 0.000 claims 3
- 201000003120 testicular cancer Diseases 0.000 claims 3
- 208000013076 thyroid tumor Diseases 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- 208000026517 ureter neoplasm Diseases 0.000 claims 3
- 201000011476 ureteral benign neoplasm Diseases 0.000 claims 3
- 208000024719 uterine cervix neoplasm Diseases 0.000 claims 3
- 206010046885 vaginal cancer Diseases 0.000 claims 3
- 208000013139 vaginal neoplasm Diseases 0.000 claims 3
- 201000005102 vulva cancer Diseases 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 2
- 239000002131 composite material Substances 0.000 claims 2
- 239000000835 fiber Substances 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000004043 dyeing Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27696909P | 2009-09-18 | 2009-09-18 | |
| US61/276,969 | 2009-09-18 | ||
| PCT/US2010/049545 WO2011035274A1 (en) | 2009-09-18 | 2010-09-20 | Use of the sparc microenvironment signature in the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013505268A JP2013505268A (ja) | 2013-02-14 |
| JP2013505268A5 true JP2013505268A5 (cg-RX-API-DMAC7.html) | 2013-11-07 |
Family
ID=43759058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012529971A Pending JP2013505268A (ja) | 2009-09-18 | 2010-09-20 | 癌の治療におけるsparc微小環境シグネチャの使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20120245089A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2478362B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2013505268A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20120092597A (cg-RX-API-DMAC7.html) |
| CN (1) | CN102576016A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2010295324B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112012008316A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2774550A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL218642A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2012003287A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ598801A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011035274A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201202657B (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8383358B2 (en) * | 2009-05-28 | 2013-02-26 | Abraxis Bioscience, Llc | Use of 2 anti-SPARC antibodies to predict response to melanoma chemotherapy |
| AU2011261240A1 (en) * | 2010-06-03 | 2013-01-10 | Abraxis Bioscience, Llc | Use of the SPARC microenvironment signature in the treatment of cancer |
| EP3539080B1 (en) * | 2016-11-10 | 2022-03-23 | F. Hoffmann-La Roche AG | Distance-based tumor classification |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5003621A (en) | 1989-11-02 | 1991-03-26 | Motorola, Inc. | Direct conversion FM receiver |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| WO2004085621A2 (en) * | 2003-03-20 | 2004-10-07 | Dana-Farber Cancer Institute, Inc. | Gene expression in breast cancer |
| ATE511550T1 (de) * | 2003-07-17 | 2011-06-15 | Pacific Edge Biotechnology Ltd | Marker zum nachweis von magenkrebs |
| JP4682152B2 (ja) * | 2003-12-31 | 2011-05-11 | ザ・ペン・ステート・リサーチ・ファンデーション | 卵巣がんの化学療法に対する抵抗性を予測および克服するための方法ならびに結腸がんの発生を予測するための方法 |
| AU2006249235B2 (en) * | 2004-05-14 | 2010-11-11 | Abraxis Bioscience, Llc | Sparc and methods of use thereof |
| GB0417740D0 (en) * | 2004-08-10 | 2004-09-08 | Uc3 | Methods and kit for the prognosis of breast cancer |
| AU2005297303B2 (en) * | 2004-10-19 | 2011-11-10 | Lsip, Llc | Novel diagnostic kit for malignant melanoma |
| CN103169729A (zh) * | 2005-02-18 | 2013-06-26 | 阿布拉科斯生物科学有限公司 | 治疗剂的组合和给予方式以及联合治疗 |
| WO2006112930A2 (en) * | 2005-02-18 | 2006-10-26 | Abraxis Bioscience, Inc. | Q3 sparc deletion mutant and uses thereof |
| RU2451521C2 (ru) * | 2006-06-16 | 2012-05-27 | Онкотерапи Сайенс, Инк. | Sparc-производные антигенные пептиды отторжения опухоли и лекарственные средства, содержащие их |
| US9675578B2 (en) * | 2006-12-14 | 2017-06-13 | Abraxis Bioscience, Llc | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| AU2008226283A1 (en) * | 2007-03-09 | 2008-09-18 | The University Of British Columbia | Assessing chemotherapy resistance of colorectal tumors by determining sparc hypermethylation |
| CN101678078B (zh) * | 2007-04-13 | 2014-12-10 | 阿布拉西斯生物科学公司 | Sparc及其使用方法 |
| AU2008260447B2 (en) * | 2007-06-01 | 2013-10-10 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
-
2010
- 2010-09-20 JP JP2012529971A patent/JP2013505268A/ja active Pending
- 2010-09-20 EP EP10817999.5A patent/EP2478362B1/en active Active
- 2010-09-20 BR BR112012008316A patent/BR112012008316A2/pt not_active IP Right Cessation
- 2010-09-20 CN CN201080047076XA patent/CN102576016A/zh active Pending
- 2010-09-20 NZ NZ598801A patent/NZ598801A/en not_active IP Right Cessation
- 2010-09-20 WO PCT/US2010/049545 patent/WO2011035274A1/en not_active Ceased
- 2010-09-20 US US13/496,385 patent/US20120245089A1/en not_active Abandoned
- 2010-09-20 CA CA2774550A patent/CA2774550A1/en not_active Abandoned
- 2010-09-20 MX MX2012003287A patent/MX2012003287A/es not_active Application Discontinuation
- 2010-09-20 AU AU2010295324A patent/AU2010295324B2/en not_active Ceased
- 2010-09-20 KR KR1020127009670A patent/KR20120092597A/ko not_active Withdrawn
-
2012
- 2012-03-14 IL IL218642A patent/IL218642A0/en unknown
- 2012-04-12 ZA ZA2012/02657A patent/ZA201202657B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Colombo et al. | HER2 targeting as a two-sided strategy for breast cancer diagnosis and treatment: Outlook and recent implications in nanomedical approaches | |
| EP2531598A4 (en) | WHSC1 AND WHSC1L1 FOR TARGET GENES TO CANCER THERAPY AND DIAGNOSIS | |
| Ren et al. | LINC00941 promotes progression of non-small cell lung cancer by sponging miR-877-3p to regulate VEGFA expression | |
| Liu et al. | The siRNA cocktail targeting VEGF and HER2 inhibition on the proliferation and induced apoptosis of gastric cancer cell | |
| Bian et al. | RETRACTED ARTICLE: Circular RNA CircCDYL Regulates Proliferation and Apoptosis in Non-Small Cell Lung Cancer Cells by Sponging miR-185-5p and Upregulating TNRC6A | |
| Bao et al. | Aberrant expression of SPAG6 and NM23 predicts poor prognosis of human osteosarcoma | |
| RU2013119459A (ru) | Комплекс ipp в качестве маркера лечения эрлотинибом | |
| Iyevleva et al. | EP209 miR-190b-5p expression is a highly reliable discriminator between ER-positive and ER-negative breast cancer | |
| Uy et al. | Case report: Alveolar rhabdomyosarcoma of the prostate presenting as lower urinary tract symptoms in a Young Adult | |
| Akdemir et al. | NIRL-11 3D-FSE IMAGING FOR RADIOSURGERY PLANNING IMPROVES BRAIN METASTASIS DETECTION AND REDUCES INTRACRANIAL RELAPSE | |
| Colleoni | IN2 Debate: The biology of breast cancer in young women is unique–In favour | |
| Ronsley et al. | NCOG-73. EFFECT OF TIME TO DIAGNOSIS IN CHILDREN WITH MALIGNANT CENTRAL NERVOUS SYSTEM TUMORS ON SURVIVAL OUTCOMES AND DISEASE-ASSOCIATED MORBIDITY: AN INSTITUTIONAL COHORT STUDY | |
| Xue et al. | VGLL4 inhibits stemness and cisplatin resistance in non-small cell lung cancer via the COL3A1/NF-κB pathway | |
| Kokkali et al. | EP210 Invasive lobular carcinoma with extracellular mucin production. Presentation of the second case diagnosed within three years in our hospital | |
| Ivanova et al. | NVTG-03 IDENTIFYING THE DRIVERS OF EARLY BRAIN METASTASES ESTABLISHMENT IN BREAST CANCER PATIENTS | |
| Mao et al. | Long Non-Coding RNA Small Nucleolar RNA Host Gene 1 and MicroRNA-100-3p Expression in Endometrial Carcinoma and Its Effect on the Proliferation and Apoptosis of Ishikawa Cells | |
| Dhanani et al. | NCOG-72. DIFFERENTIAL EFFECTS OF SURGERY AND CHEMOTHERAPY ON CHILDREN WITH POSTERIOR FOSSA BRAIN TUMORS | |
| Cluxton | IN1 YSC–Young Survival Coalition | |
| Chao et al. | Jia-Hong Chen1, 2, Wen-Chien Huang3, 4, Oluwaseun Adebayo Bamodu5, 6, Peter Mu-Hsin Chang7, 8 | |
| Hirai et al. | The role of PD-L1 in a high-grade invasive human oral squamous cell carcinoma microenvironment | |
| Carlson | AACR Annual Meeting: More Research Linking MicroRNAs to Malignancy, Metastasis | |
| Schwartzberg | The old and the new | |
| Naselli et al. | Reply from Authors re: Maurizio Brausi. Are New Technologies for Detection and Treatment of Non–Muscle-Invasive Bladder Cancer (NMIBC) So Important? A Plea For Adoption by Teaching Programs to Improve Results After Standard White Light Transurethral Resection of NMIBC. Eur Urol 2012; 61: 914–6: New Technologies May Really Improve Non–muscle-invasive Bladder Cancer Management: Now Try Them! | |
| Hesdorffer et al. | ES 03.04 Mesothelioma: Beyond the Basics | |
| Belldegrun | Panel Discussion: What the Urologist Should Know About Targeted Treatments for Renal Cancer. |